TY - JOUR
T1 - Chilean Gastric Cancer Task Force
T2 - A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
AU - Owen, Gareth I.
AU - Pinto, Mauricio P.
AU - Retamal, Ignacio N.
AU - Fernádez, María F.
AU - Cisternas, Betzabe
AU - Mondaca, Sebastian
AU - Sanchez, Cesar
AU - Galindo, Hector
AU - Nervi, Bruno
AU - Ibañez, Carolina
AU - Acevedo, Francisco
AU - Madrid, Jorge
AU - Peña, José
AU - Bravo, Maria Loreto
AU - Maturana, Maria Jose
AU - Cordova-Delgado, Miguel
AU - Romero, Diego
AU - De La Jara, Nathaly
AU - Torres, Javiera
AU - Rodriguez-Fernandez, Maria
AU - Espinoza, Manuel
AU - Balmaceda, Carlos
AU - Freire, Matías
AU - Gárate-Calderón, Valentina
AU - Crovari, Fernando
AU - Jimenez-Fonseca, Paula
AU - Carmona-Bayonas, Alberto
AU - Zwenger, Ariel
AU - Armisen, Ricardo
AU - Corvalan, Alejandro H.
AU - Garrido, Marcelo
N1 - Publisher Copyright:
© 2018 the Author(s).
PY - 2018/4
Y1 - 2018/4
N2 - Gastric cancer (GC) is the world’s second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.6 per 100,000 people and causing >3000 deaths/y. Clinical outcomes and response to “one size fits all” therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response. The Gastric Cancer Task Force is a Chilean collaborative, noninterventional study that seeks to stratify gastric adenocarcinomas using clinical outcomes and genomic, epigenomic, and protein alterations in a cohort of 200 patients. Tumor samples from the Pathology Department and the Cancer Center at UC-Christus healthcare network, Pontificia Universidad Católica de Chile will be analyzed using a panel of 143 known cancer genes (Oncomine Comprehensive Assay) at the Center of Excellence in Precision Medicine in Santiago, Chile. In addition, promoter methylation for selected genes will be performed along with tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2, among others) and Helicobacter pylori and Epstein–Barr virus status. Obtained data will be correlated to 120 clinical parameters retrieve from medical records, including general patient information, cancer history, laboratory studies, comorbidity index, chemotherapy, targeted therapies, efficacy, and follow-up. The development of a clinically meaningful classification that encompasses comprehensive clinical and molecular parameters may improve patient treatment, predict clinical outcomes, aid patient selection/stratification for clinical trials and may offer insights into future preventive and/or therapeutic strategies in patients from Latin America region. Trial registration: ClinicalTrials.gov Identifier: NCT03158571, Registered on May 18, 2017.
AB - Gastric cancer (GC) is the world’s second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.6 per 100,000 people and causing >3000 deaths/y. Clinical outcomes and response to “one size fits all” therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response. The Gastric Cancer Task Force is a Chilean collaborative, noninterventional study that seeks to stratify gastric adenocarcinomas using clinical outcomes and genomic, epigenomic, and protein alterations in a cohort of 200 patients. Tumor samples from the Pathology Department and the Cancer Center at UC-Christus healthcare network, Pontificia Universidad Católica de Chile will be analyzed using a panel of 143 known cancer genes (Oncomine Comprehensive Assay) at the Center of Excellence in Precision Medicine in Santiago, Chile. In addition, promoter methylation for selected genes will be performed along with tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2, among others) and Helicobacter pylori and Epstein–Barr virus status. Obtained data will be correlated to 120 clinical parameters retrieve from medical records, including general patient information, cancer history, laboratory studies, comorbidity index, chemotherapy, targeted therapies, efficacy, and follow-up. The development of a clinically meaningful classification that encompasses comprehensive clinical and molecular parameters may improve patient treatment, predict clinical outcomes, aid patient selection/stratification for clinical trials and may offer insights into future preventive and/or therapeutic strategies in patients from Latin America region. Trial registration: ClinicalTrials.gov Identifier: NCT03158571, Registered on May 18, 2017.
KW - Adenocarcinoma
KW - Adult
KW - Chile
KW - DNA Methylation
KW - Female
KW - Herpesvirus 4, Human
KW - Humans
KW - Male
KW - Mutation
KW - Polymorphism, Single Nucleotide
KW - Prognosis
KW - Stomach Neoplasms
KW - Tissue Array Analysis
UR - http://www.scopus.com/inward/record.url?scp=85046136481&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000010419
DO - 10.1097/MD.0000000000010419
M3 - Article
C2 - 29668600
AN - SCOPUS:85046136481
SN - 0025-7974
VL - 97
SP - 1
EP - 8
JO - Medicine (United States)
JF - Medicine (United States)
IS - 16
M1 - e0419
ER -
